Efficacy and safety of laparoscopic radical resection following neoadjuvant therapy for pancreatic ductal adenocarcinoma: A retrospective study

被引:1
|
作者
He, Yong-Gang [1 ]
Huang, Xiao-Bing [1 ]
Li, Yu-Ming [1 ]
Li, Jing [1 ]
Peng, Xue-Hui [1 ]
Huang, Wen [1 ]
Tang, Yi-Chen [1 ]
Zheng, Lu [1 ,2 ]
机构
[1] Army Med Univ, Dept Hepatobiliary, Affiliated Hosp 2, Chongqing 400037, Peoples R China
[2] Army Med Univ, Dept Hepatobiliary, Affiliated Hosp 2, 183 Xinqiao High St, Chongqing 400037, Peoples R China
关键词
Pancreatic ductal adenocarcinoma; Neoadjuvant chemotherapy; Laparoscopic pancreaticoduodenectomy; Laparoscopic radical antegrade modular pancreatosplenectomy; Complications; INTERNATIONAL STUDY-GROUP; UPFRONT RESECTION; CANCER; PANCREATICODUODENECTOMY; DEFINITION; SURGERY; TUMORS;
D O I
10.4251/wjgo.v14.i9.1785
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND Multiple studies have demonstrated that neoadjuvant chemotherapy (NACT) can prolong the overall survival of pancreatic ductal adenocarcinoma (PDAC) patients. However, most studies have focused on open surgery following NACT. AIM To investigate the efficacy and safety of laparoscopic radical resection following NACT for PDAC. METHODS We retrospectively analyzed the clinical data of 15 patients with pathologically confirmed PDAC who received NACT followed by laparoscopic radical surgery in our hospital from December 2019 to April 2022. All patients underwent abdominal contrast-enhanced computed tomography (CT) and positron emission tomography-CT before surgery to accurately assess tumor stage and exclude distant metastasis. RESULTS All 15 patients with pancreatic cancer were successfully converted to surgical resection after NACT, including 8 patients with pancreatic head cancer and 7 patients with pancreatic body and tail cancer. Among them, 13 patients received the nab-paclitaxel plus gemcitabine regimen (gemcitabine 1000 mg/m(2) plus nab-paclitaxel 125 mg/m(2) on days 1, 8, and 15 every 4 wk) and 2 patients received the modified FOLFIRINOX regimen (intravenous oxaliplatin 68 mg/m(2), irinotecan 135 mg/m(2), and leucovorin 400 mg/m(2) on day 1 and fluorouracil 400 mg/m(2) on day 1, followed by 46-h continuous infusion of fluorouracil 2400 mg/m(2)). After each treatment cycle, abdominal CT, tumor markers, and circulating tumor cell counts were reviewed to evaluate the treatment efficacy. All 15 patients achieved partial remission. The surgical procedures included laparoscopic pancreaticoduodenectomy (LPD, n = 8) and laparoscopic radical antegrade modular pancreatosplenectomy (L-RAMPS, n = 7). None of them were converted to a laparotomy. One patient with pancreatic head carcinoma was found to have portal vein involvement during the operation, and LPD combined with vascular resection and reconstruction was performed. The amount of blood loss and operation times of L-RAMPS vs LPD were 435.71 +/- 32.37 mL vs 343.75 +/- 145.01 mL and 272.52 +/- 49.14 min vs 444.38 +/- 68.63 min, respectively. The number of dissected lymph nodes was 16.87 +/- 4.10, and 3 patients had positive lymph nodes. One patient developed grade B postoperative pancreatic fistula (POPF) after L-RAMPS, and one patient experienced jaundice after LPD. None of the patients died after surgery. As of April 2022, progressive disease was noted in 4 patients, 2 patients had liver metastasis, and one had both liver metastasis and lymph node metastasis and died during the follow-up period. CONCLUSION Laparoscopic radical resection of PDAC after NACT is safe and effective if it is performed by a surgeon with rich experience in LPD and in a large center of pancreatic surgery.
引用
收藏
页码:1785 / 1797
页数:13
相关论文
共 50 条
  • [41] A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma
    Zhu, Lingyu
    Shen, Shuo
    Wang, Huan
    Zhang, Guoxiao
    Yin, Xiaoyi
    Shi, Xiaohan
    Gao, Suizhi
    Han, Jiawei
    Ren, Yiwei
    Wang, Jian
    Jiang, Hui
    Guo, Shiwei
    Jin, Gang
    BMC CANCER, 2023, 23 (01)
  • [42] Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
    Hamad, Ahmad
    Brown, Zachary J.
    Ejaz, Aslam M.
    Dillhoff, Mary
    Cloyd, Jordan M.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2021, 27 (27) : 4383 - 4394
  • [43] Pathologic complete response following neoadjuvant therapy for pancreatic ductal adenocarcinoma: defining the incidence, predictors, and outcomes
    Cloyd, Jordan M.
    Ejaz, Aslam
    Shen, Chengli
    Dillhoff, Mary
    Williams, Terence M.
    Noonan, Anne
    Pawlik, Timothy M.
    Tsung, Allan
    HPB, 2020, 22 (11) : 1569 - 1576
  • [44] Neoadjuvant therapy for pancreatic ductal adenocarcinoma:Opportunities for personalized cancer care
    Ahmad Hamad
    Zachary J Brown
    Aslam M Ejaz
    Mary Dillhoff
    Jordan M Cloyd
    World Journal of Gastroenterology, 2021, 27 (27) : 4383 - 4394
  • [45] A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma
    Lingyu Zhu
    Shuo Shen
    Huan Wang
    Guoxiao Zhang
    Xiaoyi Yin
    Xiaohan Shi
    Suizhi Gao
    Jiawei Han
    Yiwei Ren
    Jian Wang
    Hui Jiang
    Shiwei Guo
    Gang Jin
    BMC Cancer, 23
  • [46] Prognostic factors for achieving resection following neoadjuvant radiation therapy for borderline resectable pancreatic adenocarcinoma
    Dholakia, Avani Satish
    Hacker-Prietz, Amy
    Wild, Aaron Tyler
    Raman, Siva P.
    Wood, Laura D.
    Laheru, Daniel A.
    Zheng, Lei
    De Jesus-Acosta, Ana
    Dung Thi Le
    Rasheed, Zeshaan
    Ellsworth, Susannah G.
    Kumar, Rachit
    Fan, Katherine Y.
    Pawlik, Timothy M.
    Makary, Martin
    Hruban, Ralph H.
    Cameron, John L.
    Fishman, Elliott K.
    Wolfgang, Christopher Lee
    Herman, Joseph M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [47] Prognostic value of major pathological response following neoadjuvant therapy for non resectable pancreatic ductal adenocarcinoma
    Bao, Quoc Riccardo
    Frigerio, Isabella
    Tripepi, Marzia
    Marletta, Stefano
    Martignoni, Guido
    Giardino, Alessandro
    Regi, Paolo
    Scopelliti, Filippo
    Allegrini, Valentina
    Girelli, Roberto
    Pucciarelli, Salvatore
    Spolverato, Gaya
    Butturini, Giovanni
    PANCREATOLOGY, 2023, 23 (03) : 266 - 274
  • [48] CA 19-9 Normalization Following Neoadjuvant Therapy and Yield of Laparoscopy for Pancreatic Ductal Adenocarcinoma
    Fields, Brittany C.
    Vreeland, Tim
    Newhook, Timpthy E.
    Snyder, Rebecca A.
    Maxwell, Jessica E.
    Prakash, Laura R.
    Kim, Michael
    Ikoma, Naruhiko
    Lee, Jeffrey E.
    Katz, Matthew H. G.
    Tzeng, Ching-Wei D.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S63 - S64
  • [49] Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study
    Siyi Zou
    Xinjing Wang
    Haoda Chen
    Jiewei Lin
    Chenlei Wen
    Qian Zhan
    Hao Chen
    Xiongxiong Lu
    Xiaxing Deng
    Baiyong Shen
    BMC Cancer, 22
  • [50] Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study
    Zou, Siyi
    Wang, Xinjing
    Chen, Haoda
    Lin, Jiewei
    Wen, Chenlei
    Zhan, Qian
    Chen, Hao
    Lu, Xiongxiong
    Deng, Xiaxing
    Shen, Baiyong
    BMC CANCER, 2022, 22 (01)